Submissions from 2017


COX2 Induction: A Mechanism of Endocrine Breast Cancer Resistance?, B L. Clark, M A. Murphy, and Landry K. Kamdem


Impact of the OATP1B1 c.521T>C Single Nucleotide Polymorphism on the Pharmacokinetics of Exemestane in Healthy Post-Menopausal Female Volunteers, B J. Gregory, S M. Chen, M A. Murphy, D H. Atchley, and Landry K. Kamdem

Submissions from 2016


Impact of UGT2B17 Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers., S M. Chen, D H. Atchley, M A. Murphy, B J. Gurley, and Landry K. Kamdem

Submissions from 2015


Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia, L B. Ramsey, L J. Janke, M A. Payton, X Cai, S W. Paugh, S E. Karol, Landry K. Kamdem, C Cheng, R T. Williams, S Jeha, C H. Pui, W E. Evans, and M V. Relling

Submissions from 2014

17-Hydroexemestane: A Potent Inhibitor of CYP19 (Aromatase) and Substrate of CYP3A, Landry K. Kamdem, F A. David, and D Zeruesenay

Submissions from 2011


In Vitro Cytochrome P450-Mediated Metabolism of Exemestane, Landry K. Kamdem, D A. Flockhart, and Z Desta

Submissions from 2010


In Vitro and In Vivo Oxidative Metabolism and Glucuronidation of Anastrozole, Landry K. Kamdem, Y Liu, V Stearns, S A. Kadlubar, J Ramirez, S Jeter, K Shahverdi, B A. Ward, E Ogburn, M J. Ratain, D A. Flockhart, and Z Desta


Methadone: A Substrate and Mechanism-Based Inhibitor of CYP19 (Aromatase), W J. Lu, R Bies, Landry K. Kamdem, Z Desta, and D A. Flockhart